Medicaid: Fraud and Abuse Related to Controlled Substances Identified in Selected States: Congressional Testimony
DIANE Publishing, 2010 - 18 pages
Statement of Gregory D. Kutz, Managing Director, Forensic Audits and Special Investigations, GAO, discussing (1) continuing indications of fraud and abuse related to controlled substances paid for by Medicaid; (2) specific case study examples of fraudulent, improper, or abusive controlled substance activity; and (3) the effectiveness of internal controls that the federal government and selected states have in place to prevent and detect fraud and abuse related to controlled substances. Tables.
What people are saying - Write a review
We haven't found any reviews in the usual places.
65,000 Medicaid beneficiaries abuse of controlled abuse related abusive controlled substance Adderall addition ADHD Amphetamine claims processing systems CMS officials combat Medicaid Comprehensive Fraud Prevention continuing indications controlled substance prescriptions controlled substances paid deaths of Medicaid detection and monitoring dispensed controlled substance doctor shopping Drug Enforcement Administration Drug Monitoring Program drug utilization reviews effective claims processing effective fraud prevention Fentanyl fiscal years 2006 fraud and abuse fraud prevention controls Fraud Prevention Framework fraud prevention program health care providers Hydrocodone indications of fraud investigations and prosecutions Medicaid claims Medicaid fraud Medicaid offices Medicaid OIG Medicaid providers Medicare Methadone Methylphenidate MFCU officials multiple medical practitioners nursing homes Obtain Controlled Substances OxyContin PDMP pharmacies pharmacist physician assistant prescribing providers Prescription Drug Monitoring prevent and detect prevent fraud prior authorization prospective screening refills and partial related to controlled restricted recipient program Ritalin selected states include type of controlled Vicodin Xanax